Abstract
Proteins that are engineered in the laboratory for pharmaceutical use are known as therapeutic proteins. The majority of biopharmaceuticals marketed to date are recombinant therapeutic protein drugs. But how much potential does this market have? Will the shortfall in manufacturing capacity dampen its growth? Will the high cost of these drugs ever be reduced? And how imminent is the threat from biogeneric competition? These and many other questions will be answered in this comprehensive 230-page report on the market for therapeutic proteins.
In 2003, the market for therapeutic proteins grew by almost 19% to $37 billion, and is predicted to achieve sales of over $90 billion by 2010. Future growth however depends largely on the industry overcoming a number of hurdles, including drug delivery challenges and cost issues.
View Cart
